Who we are
Basilea at a glance
Vision and mission
Sustainability
Organization
25 years Basilea
What we do
Our portfolio
Disease areas
Our products and pipeline
Investor center
Investing in Basilea
Current presentation
Financial reports
Events and presentations
Annual General Meeting
Analyst coverage
Share information
Convertible bonds
Corporate Governance
Sustainability (ESG)
Stay informed
Careers
Career Openings
Working at Basilea
What we offer
News
Contact
Directions
News
News Subscription
Year
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
English
German
Filter
Show all
Show only ad hoc announcements
Dec 28. 2015
Basilea provides clinical program updates
Read more
Download
Dec 19. 2015
Final allocations of Basilea CHF 200 million senior convertible bonds
Read more
Download
Dec 10. 2015
Basilea successfully places CHF 200 million senior convertible bonds
Read more
Download
Dec 10. 2015
Basilea successfully places CHF 200 million senior convertible bonds
Read more
Download
Dec 09. 2015
Basilea launches a senior convertible bond issue
Read more
Download
Nov 05. 2015
Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
Read more
Download
Oct 23. 2015
Basilea announces that European Commission maintained isavuconazole's orphan drug status
Read more
Download
Oct 17. 2015
Basilea announces filing of registration statement for a proposed offering in the United States
Read more
Download
Oct 16. 2015
Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
Read more
Download
Oct 15. 2015
Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
Read more
Download
previous
1
…
24
25
26
…
32
next